Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2013

View Archived Issues

Romark Laboratories commences enrollment in phase III trial of nitazoxanide for influenza

Impel NeuroPharma completes proof-of-concept study for nose-to-brain drug delivery technology

New prostate cancer vaccine is safe in patients

Galectin-9, a marker of radicality of cancer resection during surgery

Bayer presents novel AR antagonist with promising in vivo activity in CRPC models

Paragazole is active against triple-negative breast cancer cells

Dosing begins in phase I/II anal cancer study of ADXS-HPV

Dainippon Sumitomo Pharma presents novel mAChR partial agonists as potential antipsychotic drugs

ASLAN Pharmaceuticals to conduct antiarthritic drug study in Singapore

Companies fund Canadian Centers of Excellence for Commercialization and Research

Galapagos begins first phase II study of GLPG-0974 in ulcerative colitis

Afferent Pharmaceuticals profiles its P2X3 receptor antagonist AF-219

Merck KGaA presents novel LPA2 receptor antagonists

New CYP17 inhibitors patented at Bristol-Myers Squibb

Oncodesign discovers novel FLT3 inhibitors

Presentations describe novel mutant-selective EGFR inhibitor CNX-2006

NanoViricides anticipates efficacy of FluCide drug candidates against H7N9 influenza

Taiho Pharmaceutical designs new SYK inhibitors

Ipsen and Oncodesign prepare novel LRRK2 inhibitors

Janssen files for European approval of simeprevir for HCV

Enrollment begins in phase I trial of Acorda's remyelinating antibody candidate for MS

Takeda files for approval of fixed-dose combination drug for hypertension in Japan

FDA approves Amitiza for additional indication

CytRx reaches SPA agreement with FDA for phase III trial of aldoxorubicin

FDA grants fast track designation to KB-001A for P. aeruginosa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...